David Pyott, former chairman and CEO of Allergan, has joined the Board of Directors of biopharmaceutical company Bioniz. Pyott brings more than 30 years of international business experience in the pharmaceutical industry to Bioniz and has been widely recognized as one of the world’s leading CEOs. He also serves as lead director and a member of the Board of Directors of Avery Dennison Corporation, a member of the Supervisory Board of Royal Philips, vice chairman of the Board of Trustees of Chapman University, a member of the Governing Board of the London Business School, president of the International Council of Ophthalmology Foundation and is a member of the Advisory Board of the Foundation of the American Academy of Ophthalmology.
“I am honored that David, a visionary and experienced pharmaceutical industry executive, has joined our board at this exciting time in Bioniz’s development,” said Nazli Azimi, MD, founder and CEO of Bioniz. “As a rapidly evolving biopharmaceutical company, David’s extensive industry experience and guidance will be invaluable as we continue to grow Bioniz and develop a first-in-class therapeutic platform with multiple-cytokine inhibitors.”
